查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701279

生物製藥市場規模、佔有率、趨勢分析報告：按分子、疾病、藥物類型、藥物開發類型、配方、地區、細分預測，2025-2030 年

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 225 Pages | 商品交期: 2-10個工作天內

價格

生物製藥市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，到2030年全球生物製藥市場規模預計將達到7,408.4億美元，2025年至2030年期間的複合年成長率為8.87%。

主要成長動力包括慢性病盛行率上升、精準醫療對生技藥品的採用增加以及生物製造技術的進步。強勁的研發投入、新型生技藥品的監管核准以及生物相似藥的日益普及進一步支持了這一成長。對單株抗體、細胞和基因療法以及重組蛋白的日益成長的需求正在重塑腫瘤學、自體免疫疾病和罕見疾病的治療方法。

生物製藥產業管道依然強勁，積極探索針對多種適應症的基因療法、基於 RNA 的療法和雙特異性抗體。 2024 年 11 月發表在《自然生物技術》上的 CRISPR 基因編輯療法對鐮狀細胞疾病和BETA地中海貧血患者顯示出持久益處。

2024年12月，Biogen和Samsung Bioepis聯合研發的Adalimumab相似藥獲得EMA核准，擴大了自體免疫疾病治療領域的市場競爭。這項策略性措施與全球生物相似藥日益普及的趨勢相吻合，解決了可負擔性挑戰並提高了優質生技藥品的可及性。隨著生物相似藥在歐洲和亞洲變得越來越普遍，各公司正在利用具有成本效益的製造策略來擴大其在全球市場的佔有率。

此外，皮下生技藥品的推出透過簡化給藥和減少對輸液中心的依賴徹底改變了患者體驗。艾伯維（AbbVie）的Infliximab單抗皮下製劑於 2025 年 2 月核准，預計將提高依從性和患者滿意度，並佔據顯著的市場佔有率。

作為行業進步的一部分，龍沙作為白金贊助商參加了 11 月 20 日至 22 日在新加坡舉行的 2024 年生物製劑製造會議，重點關注大規模生技藥品製造的創新。這項活動重點在於塑造下一代高效療法的生技藥品製劑製造趨勢，包括一次性生物反應器、製程強化和人工智慧主導的生技藥品開發。

這些策略舉措凸顯了公司對生物製藥創新、市場擴張和監管進步的關注，旨在改善全球患者的治療效果。

生物製藥市場報告重點

  • 根據分子類型，單株抗體將在 2024 年佔整個市場的 61.05%，由於其高特異性、廣泛的治療應用以及在腫瘤學和自體免疫疾病方面不斷成長的需求，佔據市場主導地位。由於荷爾蒙在內分泌學和代謝疾病治療中的應用日益廣泛，預計預測期內荷爾蒙領域將以強勁的複合年成長率成長。
  • 根據疾病，由於癌症盛行率上升和生技藥品核准增加，腫瘤學在市場上佔據最大收入佔有率，到 2024 年將佔整個市場的 31.00%。然而，預計免疫學領域在預測期內將以最快的速度成長。
  • 根據藥品類型，專有（品牌）生物製藥在 2024 年佔據最大的銷售佔有率，佔整個市場的 77.86%。然而，由於監管部門核准的增加和成本節約舉措，生物相似藥預計將在預測期內實現最快的複合年成長率。
  • 根據藥物開發類型，生物製藥開發外包將佔據市場主導地位，到 2024 年將佔整個市場的 56.15%。
  • 根據配方，注射生技藥品（靜脈注射、肌肉注射、皮下注射）在 2024 年佔據最大的收入佔有率，佔市場佔有率的 92.55%。然而，由於非侵入性藥物傳輸技術的進步，吸入式和鼻腔生技藥品預計將顯著成長。
  • 根據給藥途徑，腸外給藥（靜脈注射、肌肉注射和肌肉注射）在 2024 年佔據 88.74% 的市場佔有率，佔據主導地位。預計吸入和鼻腔給藥將在預測期內獲得發展動力。
  • 根據製劑類型，由於嚴格的法律規範和生技藥品治療的複雜性，處方藥將在 2024 年佔據市場主導地位，佔總收入的 96.90%。
  • 按分銷管道分類，醫院和專科診所等非零售通路在 2024 年成為主要分銷管道，佔總銷售額的 55.70%。
  • 生物製藥產業的主要企業包括安進、輝瑞、諾華、賽諾菲、默克、羅氏控股、百健、Astra Zeneca、禮來和拜耳。
  • 2024年6月，再生元製藥公司宣布，Kevzara（通用名： Sarilumab）已獲得美國FDA核准，用於治療2歲以上患者的活動性多關節型幼年特發性關節炎（pJIA）。此次核准為患有這種慢性發炎疾病的兒童提供了新的治療選擇。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章生物製藥市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定價分析

第4章生物製藥市場：分子類型業務分析

  • 2024 年和 2030 年分子類型市場佔有率
  • 分子類型細分儀表板
  • 2018-2030 年按分子類型分類的市場規模、預測與趨勢分析
  • 單株抗體
  • 干擾素
  • 胰島素
  • 生長和凝血因子
  • 促紅血球生成素
  • 疫苗
  • 荷爾蒙
  • 其他

第5章生物製藥市場：疾病業務分析

  • 2024年及2030年的疾病市場佔有率
  • 疾病細分儀表板
  • 市場規模、預測與趨勢分析（按疾病，2018-2030 年）
  • 腫瘤學
  • 血液系統疾病
  • 代謝紊亂
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 免疫學
  • 其他

第6章生物製藥市場：按藥物類型分類的業務分析

  • 2024 年和 2030 年各藥物類型的市場佔有率
  • 藥品類型細分儀表板
  • 2018-2030 年藥品市場規模、預測及趨勢分析
  • 獨特的品牌

第7章生物製藥市場：藥物開發類型業務分析

  • 2024 年和 2030 年藥物開發類型市場佔有率
  • 藥物開發類型細分儀表板
  • 按藥物開發類型分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 外包
  • 內部

第8章生物製藥市場：製劑業務分析

  • 2024年及2030年的醫藥市場佔有率
  • 配方細分儀表板
  • 2018 年至 2030 年市場規模、預測與趨勢分析（按配方）
  • 注射劑（靜脈注射、肌肉注射、皮下注射）
  • 吸入/鼻噴劑
  • 其他

第9章生物製藥市場：給藥途徑業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 給藥途徑細分儀表板
  • 按管理路線分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 腸外給藥（靜脈注射、肌肉注射、皮下注射）
  • 吸入/鼻腔
  • 其他

第10章生物製藥市場：製劑類型業務分析

  • 2024 年和 2030 年按製劑類型分類的市場佔有率
  • 處方類型細分儀表板
  • 2018-2030 年按製劑類型分類的市場規模、預測與趨勢分析
  • 處方藥
  • 場外交易（OTC）

第 11 章生物製藥市場：通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 市場規模、預測與趨勢分析（按分銷管道，2018-2030 年）
  • 零售
  • 非零售

第 12 章生物製藥市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第13章競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GSK plc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Amgen Inc.
Product Code: GVR-4-68040-534-1

Biopharmaceutical Market Growth & Trends:

The global biopharmaceutical market size is anticipated to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.

The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.

In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.

Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie's subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.

As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20-22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.

These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Biopharmaceutical Market Report Highlights:

  • Based on molecule type, monoclonal antibodies dominated the market in 2024, accounting for 61.05% of the total revenue due to their high specificity, broad therapeutic applications, and growing demand in oncology and autoimmune disorders. The hormone segment is projected to grow at a robust CAGR over the forecast period, driven by increasing adoption in endocrinology and metabolic disease treatments.
  • Based on disease, oncology led the market with the largest revenue share in 2024, accounting for 31.00% of the total market due to the rising prevalence of cancer and increasing approvals of biologic therapies. However, the immunology segment is expected to grow at the fastest rate over the forecast period.
  • Based on drug type, proprietary (branded) biopharmaceuticals held the largest revenue share in 2024, comprising 77.86% of the total market, attributed to continuous R&D investments and strong patent protection. However, biosimilars are expected to witness the fastest CAGR over the forecast period due to regulatory approvals and increasing cost-saving initiatives.
  • Based on drug development type, outsourced biopharmaceutical development dominated the market in 2024, accounting for 56.15% of the total revenue as companies increasingly leverage contract development and manufacturing organizations (CDMOs) to optimize costs and accelerate commercialization.
  • Based on formulation, injectable biologics (IV, IM, SC) held the largest revenue share in 2024, comprising 92.55% of the market, driven by their systemic absorption and effectiveness. However, inhalation and nasal biologics are expected to witness significant growth due to advancements in non-invasive drug delivery.
  • Based on route of administration, parenteral administration (IV, IM, SC) led the market in 2024, with an 88.74% share, as most biologics require systemic delivery. Inhalation and nasal routes are expected to gain traction over the forecast period.
  • Based on prescription type, prescription medicines dominated the market in 2024, accounting for 96.90% of the total revenue due to stringent regulatory oversight and the complexity of biologic therapies.
  • Based on sales channel, non-retail channels, including hospitals and specialty clinics, emerged as the dominant distribution channel in 2024, accounting for 55.70% of total revenue, reflecting the need for controlled administration and storage of biologics.
  • Key players operating in the biopharmaceutical industry include Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi; Merck & Co.; Roche Holding AG; Biogen Inc.; AstraZeneca; Eli Lilly and Company; and Bayer AG.
  • In June 2024, Regeneron Pharmaceuticals, Inc. announced the approval of Kevzara (sarilumab) by the U.S. FDA for the treatment of active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years and older. This approval provides a new treatment option for children affected by this chronic inflammatory condition.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule Type
    • 1.2.2. Disease
    • 1.2.3. Drug Type
    • 1.2.4. Drug Development Type
    • 1.2.5. Formulation
    • 1.2.6. Route of Administration
    • 1.2.7. Prescription Type
    • 1.2.8. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

  • 4.1. Molecule Type Market Share, 2024 & 2030
  • 4.2. Molecule Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type , 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibody
    • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
  • 4.5. Interferon
    • 4.5.1. Interferon Market, 2018 - 2030 (USD Million)
  • 4.6. Insulin
    • 4.6.1. Insulin Market, 2018 - 2030 (USD Million)
  • 4.7. Growth and Coagulation Factor
    • 4.7.1. Growth and Coagulation Factor Market, 2018 - 2030 (USD Million)
  • 4.8. Erythropoietin
    • 4.8.1. Erythropoietin Market, 2018 - 2030 (USD Million)
  • 4.9. Vaccine
    • 4.9.1. Vaccine Market, 2018 - 2030 (USD Million)
  • 4.10. Hormone
    • 4.10.1. Hormone Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2024 & 2030
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. Blood Disorder
    • 5.5.1. Blood Disorder Market, 2018 - 2030 (USD Million)
  • 5.6. Metabolic Disease
    • 5.6.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Infectious Disease
    • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Million)
  • 5.8. Cardiovascular Disease
    • 5.8.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 5.9. Neurological Disease
    • 5.9.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 5.10. Immunology
    • 5.10.1. Immunology Market, 2018 - 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

  • 6.1. Drug Type Market Share, 2024 & 2030
  • 6.2. Drug Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 6.4. Proprietary (Branded)
    • 6.4.1. Proprietary (Branded) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Biosimilars
      • 6.4.2.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

  • 7.1. Drug Development Type Market Share, 2024 & 2030
  • 7.2. Drug Development Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2018 to 2030 (USD Million)
  • 7.4. Outsource
    • 7.4.1. Outsource Market, 2018 - 2030 (USD Million)
  • 7.5. In-house
    • 7.5.1. In-house Market, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

  • 8.1. Formulation Market Share, 2024 & 2030
  • 8.2. Formulation Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
  • 8.4. Injectables (IV, IM, SC)
    • 8.4.1. Injectables (IV, IM, SC) Market, 2018 - 2030 (USD Million)
  • 8.5. Inhalation/Nasal Sprays
    • 8.5.1. Inhalation/Nasal Sprays Market, 2018 - 2030 (USD Million)
  • 8.6. Other Formulations
    • 8.6.1. Other Formulations Market, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

  • 9.1. Route of Administration Market Share, 2024 & 2030
  • 9.2. Route of Administration Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 9.4. Parenteral (IV, IM, SC)
    • 9.4.1. Parenteral (IV, IM, SC) Market, 2018 - 2030 (USD Million)
  • 9.5. Inhalation/Nasal
    • 9.5.1. Inhalation/Nasal Market, 2018 - 2030 (USD Million)
  • 9.6. Other Routes
    • 9.6.1. Other Routes Market, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

  • 10.1. Prescription Type Market Share, 2024 & 2030
  • 10.2. Prescription Type Segment Dashboard
  • 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2018 to 2030 (USD Million)
  • 10.4. Prescription Medicines
    • 10.4.1. Prescription Medicines Market, 2018 - 2030 (USD Million)
  • 10.5. Over-the-counter (OTC) Medicines
    • 10.5.1. Over-the-counter (OTC) Medicines Market, 2018 - 2030 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

  • 11.1. Sales Channel Market Share, 2024 & 2030
  • 11.2. Sales Channel Segment Dashboard
  • 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 11.4. Retail Pharmacies
    • 11.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 11.5. Non-retail
    • 11.5.1. Non-retail Market, 2018 - 2030 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

  • 12.1. Regional Market Share Analysis, 2024 & 2030
  • 12.2. Regional Market Dashboard
  • 12.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 12.4. North America
    • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 12.4.2. U.S.
      • 12.4.2.1. Key Country Dynamics
      • 12.4.2.2. Target Disease Prevalence
      • 12.4.2.3. Regulatory Framework
      • 12.4.2.4. Reimbursement Framework
      • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.4.3. Canada
      • 12.4.3.1. Key Country Dynamics
      • 12.4.3.2. Target Disease Prevalence
      • 12.4.3.3. Regulatory Framework
      • 12.4.3.4. Reimbursement Framework
      • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.4.4. Mexico
      • 12.4.4.1. Key Country Dynamics
      • 12.4.4.2. Target Disease Prevalence
      • 12.4.4.3. Regulatory Framework
      • 12.4.4.4. Reimbursement Framework
      • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5. Europe
    • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.2. UK
      • 12.5.2.1. Key Country Dynamics
      • 12.5.2.2. Target Disease Prevalence
      • 12.5.2.3. Regulatory Framework
      • 12.5.2.4. Reimbursement Framework
      • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.3. Germany
      • 12.5.3.1. Key Country Dynamics
      • 12.5.3.2. Target Disease Prevalence
      • 12.5.3.3. Regulatory Framework
      • 12.5.3.4. Reimbursement Framework
      • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.4. France
      • 12.5.4.1. Key Country Dynamics
      • 12.5.4.2. Target Disease Prevalence
      • 12.5.4.3. Regulatory Framework
      • 12.5.4.4. Reimbursement Framework
      • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.5. Italy
      • 12.5.5.1. Key Country Dynamics
      • 12.5.5.2. Target Disease Prevalence
      • 12.5.5.3. Regulatory Framework
      • 12.5.5.4. Reimbursement Framework
      • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.6. Spain
      • 12.5.6.1. Key Country Dynamics
      • 12.5.6.2. Target Disease Prevalence
      • 12.5.6.3. Regulatory Framework
      • 12.5.6.4. Reimbursement Framework
      • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.7. Denmark
      • 12.5.7.1. Key Country Dynamics
      • 12.5.7.2. Target Disease Prevalence
      • 12.5.7.3. Regulatory Framework
      • 12.5.7.4. Reimbursement Framework
      • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.8. Sweden
      • 12.5.8.1. Key Country Dynamics
      • 12.5.8.2. Target Disease Prevalence
      • 12.5.8.3. Regulatory Framework
      • 12.5.8.4. Reimbursement Framework
      • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.9. Norway
      • 12.5.9.1. Key Country Dynamics
      • 12.5.9.2. Target Disease Prevalence
      • 12.5.9.3. Regulatory Framework
      • 12.5.9.4. Reimbursement Framework
      • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6. Asia Pacific
    • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.2. Japan
      • 12.6.2.1. Key Country Dynamics
      • 12.6.2.2. Target Disease Prevalence
      • 12.6.2.3. Regulatory Framework
      • 12.6.2.4. Reimbursement Framework
      • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.3. China
      • 12.6.3.1. Key Country Dynamics
      • 12.6.3.2. Target Disease Prevalence
      • 12.6.3.3. Regulatory Framework
      • 12.6.3.4. Reimbursement Framework
      • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.4. India
      • 12.6.4.1. Key Country Dynamics
      • 12.6.4.2. Target Disease Prevalence
      • 12.6.4.3. Regulatory Framework
      • 12.6.4.4. Reimbursement Framework
      • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.5. Australia
      • 12.6.5.1. Key Country Dynamics
      • 12.6.5.2. Target Disease Prevalence
      • 12.6.5.3. Regulatory Framework
      • 12.6.5.4. Reimbursement Framework
      • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.6. South Korea
      • 12.6.6.1. Key Country Dynamics
      • 12.6.6.2. Target Disease Prevalence
      • 12.6.6.3. Regulatory Framework
      • 12.6.6.4. Reimbursement Framework
      • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.7. Thailand
      • 12.6.7.1. Key Country Dynamics
      • 12.6.7.2. Target Disease Prevalence
      • 12.6.7.3. Regulatory Framework
      • 12.6.7.4. Reimbursement Framework
      • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7. Latin America
    • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.7.2. Brazil
      • 12.7.2.1. Key Country Dynamics
      • 12.7.2.2. Target Disease Prevalence
      • 12.7.2.3. Regulatory Framework
      • 12.7.2.4. Reimbursement Framework
      • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.7.3. Argentina
      • 12.7.3.1. Key Country Dynamics
      • 12.7.3.2. Target Disease Prevalence
      • 12.7.3.3. Regulatory Framework
      • 12.7.3.4. Reimbursement Framework
      • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8. Middle East and Africa
    • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.2. South Africa
      • 12.8.2.1. Key Country Dynamics
      • 12.8.2.2. Target Disease Prevalence
      • 12.8.2.3. Regulatory Framework
      • 12.8.2.4. Reimbursement Framework
      • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.3. Saudi Arabia
      • 12.8.3.1. Key Country Dynamics
      • 12.8.3.2. Target Disease Prevalence
      • 12.8.3.3. Regulatory Framework
      • 12.8.3.4. Reimbursement Framework
      • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.4. UAE
      • 12.8.4.1. Key Country Dynamics
      • 12.8.4.2. Target Disease Prevalence
      • 12.8.4.3. Regulatory Framework
      • 12.8.4.4. Reimbursement Framework
      • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.5. Kuwait
      • 12.8.5.1. Key Country Dynamics
      • 12.8.5.2. Target Disease Prevalence
      • 12.8.5.3. Regulatory Framework
      • 12.8.5.4. Reimbursement Framework
      • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

  • 13.1. Participant Overview
  • 13.2. Company Market Position Analysis
  • 13.3. Company Categorization
  • 13.4. Strategy Mapping
  • 13.5. Company Profiles/Listing
    • 13.5.1. F. Hoffmann-La Roche Ltd
      • 13.5.1.1. Overview
      • 13.5.1.2. Financial Performance
      • 13.5.1.3. Product Benchmarking
      • 13.5.1.4. Strategic Initiatives
    • 13.5.2. Novartis AG
      • 13.5.2.1. Overview
      • 13.5.2.2. Financial Performance
      • 13.5.2.3. Product Benchmarking
      • 13.5.2.4. Strategic Initiatives
    • 13.5.3. AbbVie Inc.
      • 13.5.3.1. Overview
      • 13.5.3.2. Financial Performance
      • 13.5.3.3. Product Benchmarking
      • 13.5.3.4. Strategic Initiatives
    • 13.5.4. Johnson & Johnson Services, Inc.
      • 13.5.4.1. Overview
      • 13.5.4.2. Financial Performance
      • 13.5.4.3. Product Benchmarking
      • 13.5.4.4. Strategic Initiatives
    • 13.5.5. Merck & Co., Inc.
      • 13.5.5.1. Overview
      • 13.5.5.2. Financial Performance
      • 13.5.5.3. Product Benchmarking
      • 13.5.5.4. Strategic Initiatives
    • 13.5.6. Pfizer Inc.
      • 13.5.6.1. Overview
      • 13.5.6.2. Financial Performance
      • 13.5.6.3. Product Benchmarking
      • 13.5.6.4. Strategic Initiatives
    • 13.5.7. Bristol-Myers Squibb Company
      • 13.5.7.1. Overview
      • 13.5.7.2. Financial Performance
      • 13.5.7.3. Product Benchmarking
      • 13.5.7.4. Strategic Initiatives
    • 13.5.8. Sanofi
      • 13.5.8.1. Overview
      • 13.5.8.2. Financial Performance
      • 13.5.8.3. Product Benchmarking
      • 13.5.8.4. Strategic Initiatives
    • 13.5.9. GSK plc.
      • 13.5.9.1. Overview
      • 13.5.9.2. Financial Performance
      • 13.5.9.3. Product Benchmarking
      • 13.5.9.4. Strategic Initiatives
    • 13.5.10. AstraZeneca
      • 13.5.10.1. Overview
      • 13.5.10.2. Financial Performance
      • 13.5.10.3. Product Benchmarking
      • 13.5.10.4. Strategic Initiatives
    • 13.5.11. Takeda Pharmaceutical Company Limited
      • 13.5.11.1. Overview
      • 13.5.11.2. Financial Performance
      • 13.5.11.3. Product Benchmarking
      • 13.5.11.4. Strategic Initiatives
    • 13.5.12. Biogen
      • 13.5.12.1. Overview
      • 13.5.12.2. Financial Performance
      • 13.5.12.3. Product Benchmarking
      • 13.5.12.4. Strategic Initiatives
    • 13.5.13. Eli Lilly and Company
      • 13.5.13.1. Overview
      • 13.5.13.2. Financial Performance
      • 13.5.13.3. Product Benchmarking
      • 13.5.13.4. Strategic Initiatives
    • 13.5.14. Novo Nordisk A/S
      • 13.5.14.1. Overview
      • 13.5.14.2. Financial Performance
      • 13.5.14.3. Product Benchmarking
      • 13.5.14.4. Strategic Initiatives
    • 13.5.15. Amgen Inc.
      • 13.5.15.1. Overview
      • 13.5.15.2. Financial Performance
      • 13.5.15.3. Product Benchmarking
      • 13.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biopharmaceutical Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 7 Global Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 8 Global Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 9 Global Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Global Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 11 Global Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 12 North America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 13 North America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 North America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 North America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 16 North America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 17 North America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 18 North America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 North America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 20 North America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 21 US Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 22 US Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 23 US Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 US Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 25 US Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 26 US Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 US Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 28 US Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 29 Canada Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 30 Canada Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 Canada Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Canada Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 33 Canada Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 34 Canada Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Canada Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 36 Canada Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 37 Mexico Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 38 Mexico Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 39 Mexico Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 40 Mexico Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 41 Mexico Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 42 Mexico Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Mexico Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 44 Mexico Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 45 Europe Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 46 Europe Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 47 Europe Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 48 Europe Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 49 Europe Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 50 Europe Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 51 Europe Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Europe Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 53 Europe Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 54 UK Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 55 UK Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 UK Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 57 UK Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 58 UK Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 59 UK Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 UK Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 61 UK Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 62 Germany Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 63 Germany Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 64 Germany Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 65 Germany Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 66 Germany Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 67 Germany Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Germany Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 69 Germany Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 70 France Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 71 France Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 France Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 73 France Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 74 France Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 75 France Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 France Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 77 France Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 78 Italy Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 79 Italy Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 80 Italy Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 81 Italy Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 82 Italy Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 83 Italy Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Italy Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 85 Italy Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 86 Spain Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 87 Spain Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 Spain Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 89 Spain Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 90 Spain Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 91 Spain Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Spain Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 93 Spain Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 94 Norway Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95 Norway Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 96 Norway Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 97 Norway Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 98 Norway Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 99 Norway Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Norway Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 101 Norway Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 102 Denmark Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 103 Denmark Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 104 Denmark Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 105 Denmark Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 106 Denmark Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 107 Denmark Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 108 Denmark Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 109 Denmark Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 110 Sweden Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 111 Sweden Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 112 Sweden Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 113 Sweden Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 114 Sweden Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 115 Sweden Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 116 Sweden Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 117 Sweden Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 118 Asia Pacific Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 119 Asia Pacific Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 120 Asia Pacific Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 121 Asia Pacific Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 122 Asia Pacific Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 123 Asia Pacific Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 124 Asia Pacific Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 125 Asia Pacific Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 126 Asia Pacific Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 127 Japan Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 128 Japan Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 129 Japan Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 130 Japan Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 131 Japan Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 132 Japan Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 133 Japan Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 134 Japan Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 135 China Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 136 China Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 137 China Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 138 China Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 139 China Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 140 China Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 141 China Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 142 China Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 143 India Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 144 India Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 145 India Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 146 India Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 147 India Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 148 India Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 149 India Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 150 India Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 151 Australia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 152 Australia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 153 Australia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 154 Australia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 155 Australia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 156 Australia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 157 Australia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 158 Australia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 159 South Korea Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 160 South Korea Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 161 South Korea Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 162 South Korea Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 163 South Korea Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 164 South Korea Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 165 South Korea Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 166 South Korea Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 167 Thailand Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 168 Thailand Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 169 Thailand Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 170 Thailand Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 171 Thailand Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 172 Thailand Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 173 Thailand Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 174 Thailand Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 175 Latin America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 176 Latin America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 177 Latin America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 178 Latin America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 179 Latin America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 180 Latin America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 181 Latin America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 182 Latin America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 183 Latin America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 184 Brazil Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 185 Brazil Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 186 Brazil Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 187 Brazil Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 188 Brazil Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 189 Brazil Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 190 Brazil Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 191 Brazil Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 192 Argentina Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 193 Argentina Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 194 Argentina Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 195 Argentina Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 196 Argentina Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 197 Argentina Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 198 Argentina Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 199 Argentina Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 200 Middle East & Africa Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 201 Middle East & Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 202 Middle East & Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 203 Middle East & Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 204 Middle East & Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 205 Middle East & Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 206 Middle East & Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 207 Middle East & Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 208 Middle East & Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 209 South Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 210 South Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 211 South Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 212 South Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 213 South Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 214 South Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 215 South Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 216 South Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 217 Saudi Arabia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 218 Saudi Arabia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 219 Saudi Arabia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 220 Saudi Arabia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 221 Saudi Arabia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 222 Saudi Arabia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 223 Saudi Arabia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 224 Saudi Arabia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 225 UAE Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 226 UAE Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 227 UAE Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 228 UAE Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 229 UAE Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 230 UAE Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 231 UAE Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 232 UAE Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 233 Kuwait Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 234 Kuwait Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 235 Kuwait Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 236 Kuwait Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 237 Kuwait Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 238 Kuwait Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 239 Kuwait Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 240 Kuwait Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD billion)
  • Fig. 16 Market dynamics
  • Fig. 17 Global large pharma R&D spending in 2018 - 2023 (USD Billion)
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Biopharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 21 Biopharmaceutical market: Molecule type movement analysis
  • Fig. 22 Monoclonal antibody market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Interferon market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 24 Insulin market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 25 Growth and coagulation factor market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Hormone market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Biopharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Biopharmaceutical market: Disease movement analysis
  • Fig. 32 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Blood disorder market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Metabolic disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 35 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Cardiovascular disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Neurological disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Immunology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 40 Biopharmaceutical market: Drug Type outlook and key takeaways
  • Fig. 41 Biopharmaceutical market: Drug type movement analysis
  • Fig. 42 Proprietary (Branded) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Biosimilars market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Biopharmaceutical market: Drug development type outlook and key takeaways
  • Fig. 45 Biopharmaceutical market: Drug development type movement analysis
  • Fig. 46 Outsource market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 In-house market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Biopharmaceutical market: Formulation outlook and key takeaways
  • Fig. 49 Biopharmaceutical market: Formulation movement analysis
  • Fig. 50 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 51 Inhalation/nasal sprays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Other formulations market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 Biopharmaceutical market: Prescription outlook and key takeaways
  • Fig. 54 Biopharmaceutical market: Prescription movement analysis
  • Fig. 55 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 OTC market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Biopharmaceuticals market: Route of administration outlook and key takeaways
  • Fig. 58 Biopharmaceuticals market: Route of administration movement analysis
  • Fig. 59 Parenteral market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 Inhalations/Nasal market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Other routes of administration market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 62 Biopharmaceuticals market Sales channel market outlook and key takeaways
  • Fig. 63 Biopharmaceuticals market Sales channel market movement analysis
  • Fig. 64 Retail market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Non-retail market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Biopharmaceutical market revenue, by region, 2024 & 2030 (USD Billion)
  • Fig. 67 Regional marketplace: Key takeaways
  • Fig. 68 North America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Key country dynamics
  • Fig. 70 U.S. biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Cancer incidence, 2022-2045
  • Fig. 72 U.S. healthcare system: money flow
  • Fig. 73 Key country dynamics
  • Fig. 74 Canada biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 75 Cancer incidence, 2022-2045
  • Fig. 76 Key country dynamics
  • Fig. 77 Mexico biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 78 Cancer incidence, 2022-2045
  • Fig. 79 Regulatory framework
  • Fig. 80 Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 81 Obesity and diabetes in European nations
  • Fig. 82 Causes of mortality in Europe
  • Fig. 83 Key country dynamics
  • Fig. 84 UK biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 85 Cancer incidence, 2022-2045
  • Fig. 86 Key country dynamics
  • Fig. 87 Germany biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 88 Cancer incidence, 2022-2045
  • Fig. 89 R&D spending
  • Fig. 90 Exclusivity formula
  • Fig. 91 Germany insurance coverage
  • Fig. 92 Key country dynamics
  • Fig. 93 France biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 94 Cancer incidence, 2022-2045
  • Fig. 95 Key country dynamics
  • Fig. 96 Italy biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 97 Cancer incidence, 2022-2045
  • Fig. 98 Key country dynamics
  • Fig. 99 Spain biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 100 Cancer incidence, 2022-2045
  • Fig. 101 Key country dynamics
  • Fig. 102 Denmark biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Cancer Incidence, 2022-2045
  • Fig. 104 Key country dynamics
  • Fig. 105 Sweden biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 106 Cancer incidence 2022-2045
  • Fig. 107 Key country dynamics
  • Fig. 108 Norway biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 109 Cancer incidence, 2022-2045
  • Fig. 110 Rest of Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 111 Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 112 Key country dynamics
  • Fig. 113 Japan biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 114 Cancer incidence, 2022-2045
  • Fig. 115 Japan pharmaceutical registration
  • Fig. 116 Key country dynamics
  • Fig. 117 China biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 118 Cancer incidence, 2022-2045
  • Fig. 119 Regulatory details: China
  • Fig. 120 Key country dynamics
  • Fig. 121 India biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 122 Cancer incidence, 2018 - 2030
  • Fig. 123 Key country dynamics
  • Fig. 124 Australia biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 125 Cancer incidence, 2018 - 2030
  • Fig. 126 Key country dynamics
  • Fig. 127 Thailand biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 128 Cancer incidence, 2018 - 2030
  • Fig. 129 Key country dynamics
  • Fig. 130 South Korea biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 Cancer incidence, 2018 - 2030
  • Fig. 132 Rest of Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 134 Key country dynamics
  • Fig. 135 Brazil biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 136 Cancer incidence, 2018 - 2030
  • Fig. 137 Key country dynamics
  • Fig. 138 Argentina biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 139 Cancer incidence, 2018 - 2030
  • Fig. 140 Rest of Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 141 MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 142 Key country dynamics
  • Fig. 143 South Africa biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 144 Cancer incidence, 2018 - 2030
  • Fig. 145 Key country dynamics
  • Fig. 146 Saudi Arabia biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 147 Cancer incidence, 2018 - 2030
  • Fig. 148 Key country dynamics
  • Fig. 149 UAE biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 150 Cancer incidence, 2018 - 2030
  • Fig. 151 UAE import and export details
  • Fig. 152 Key country dynamics
  • Fig. 153 Kuwait biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 154 Cancer incidence, 2018 - 2030
  • Fig. 155 Kuwait imports and export details
  • Fig. 156 Rest of MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 157 Company/competition categorization
  • Fig. 160 Strategy mapping